文献速递心脑血管急症

采用高敏肌钙蛋白T重新校准HEART评分

HEART Score Recalibration Using Higher Sensitivity Troponin T.
PubMed 文献 · Ann Emerg Med · 2023-06-10
一句话结论重新校准HEART评分≤3分(肌钙蛋白阈值改为检测限/定量限)可在单次高敏肌钙蛋白T下安全早期离院,但需在独立前瞻队列中验证后才能实施。

该研究为英国2中心前瞻性队列(2018年,NCT03619733)并二次分析英国(2011年)和美国(2018年)两个前瞻性队列,共纳入3752例疑似急性冠脉综合征患者,将HEART与TIMI评分中肌钙蛋白子项阈值从99百分位改为检测限(LOD)或定量限(LOQ)进行重新校准。30天主要不良心血管事件(MACE)发生率为8.8%(330/3752)。重新校准HEART≤3分排除MACE的敏感性为98.6%(95%CI 96.5–99.5),高于原版HEART≤3分的96.1%(95%CI 93.4–97.9),但特异性由53.8%降至50.8%;重新校准HEART≤3分预计比单用hs-cTnT<LOD/LOQ多离院14%的患者。作者认为重新校准HEART≤3分是可行且安全的早期离院策略,但需在独立前瞻队列中用其他hs-cTn检测方法进一步验证。

要点

  • 疑似ACS患者中,重新校准HEART≤3分排除30天MACE的敏感性为98.6%(95%CI 96.5–99.5),原版HEART≤3分为96.1%(95%CI 93.4–97.9)。
  • 重新校准HEART≤3分预计比单用hs-cTnT<LOD/LOQ多离院14%的患者,但特异性由原版HEART的53.8%降至50.8%。
  • 重新校准TIMI≤1分排除MACE的敏感性为96.1%(95%CI 93.4–97.9),原版TIMI≤1分为79.7%(95%CI 74.9–83.9)。
  • 非缺血性心电图联合hs-cTnT<LOD/LOQ排除MACE的敏感性为99.1%(95%CI 0.974–0.998),联合hs-cTnT<99百分位为79.7%(95%CI 0.749–0.839)。
  • 作者认为重新校准HEART≤3分是可行且安全的早期离院策略,但实施前需在独立前瞻队列中用其他hs-cTn检测方法进一步验证。

适用人群与场景

  • 疑似急性冠脉综合征(ACS)的患者,来自英国2中心前瞻性队列(2018年)及英国(2011年)和美国(2018年)两个前瞻性队列的二次分析,共3752例(英国3003例、美国749例),中位年龄58岁,48%为女性。

诊断标准与关键阈值

  • 重新校准HEART评分:将肌钙蛋白子项评分阈值从99百分位改为检测限(LOD,英国队列)或定量限(LOQ,美国队列),HEART≤3分用于排除MACE。
  • 重新校准TIMI评分:同样将肌钙蛋白子项阈值改为LOD/LOQ,TIMI≤1分用于排除MACE。
  • 主要结局MACE定义为30天内裁定1型心肌梗死、紧急冠状动脉血运重建和全因死亡。

研究设计与关键结果

  • 研究类型:英国2中心前瞻性队列研究(2018年,NCT03619733)并二次分析英国(2011年)和美国(2018年)两个前瞻性队列;共3752例(英国3003例、美国749例);中位年龄58岁,48%为女性;30天MACE发生率8.8%(330/3752)。
  • 重新校准HEART≤3分排除MACE的敏感性98.6%(95%CI 96.5–99.5),原版HEART≤3分为96.1%(95%CI 93.4–97.9)。
  • 重新校准TIMI≤1分排除MACE的敏感性96.1%(95%CI 93.4–97.9),原版TIMI≤1分为79.7%(95%CI 74.9–83.9)。
  • 非缺血性心电图联合hs-cTnT<LOD/LOQ排除MACE的敏感性99.1%(95%CI 0.974–0.998),联合hs-cTnT<99百分位为79.7%(95%CI 0.749–0.839)。
  • 重新校准HEART≤3分预计比单用hs-cTnT<LOD/LOQ多离院14%的患者;重新校准HEART特异性50.8%,原版HEART特异性53.8%。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究(含2中心前瞻性队列及两个前瞻性队列的二次分析)。
  • 局限:作者指出该发现需在独立前瞻队列中使用其他hs-cTn检测方法进一步验证后才能实施。

对床旁实践的改变

  • 作者认为,采用单次就诊hs-cTnT时,重新校准HEART评分≤3分是可行且安全的早期离院策略;但作者同时指出,在实施前需在独立前瞻队列中用其他hs-cTn检测方法进一步验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: We examined the diagnostic performance of a recalibrated History, Electrocardiogram, Age, Risk factors, Troponin (HEART), and Thrombolysis in Myocardial Infarction (TIMI) score in patients with suspected acute cardiac syndrome (ACS). Recalibration of troponin thresholds was performed, including shifting from the 99th percentile to the limit of detection (LOD) or to the limit of quantification (LOQ) We compared the discharge potential and safety of the recalibrated composite scores using a single presentation high-sensitivity cardiac troponin (hs-cTn) T to the conventional scores and with a LOD/LOQ troponin strategy alone.

METHODS: We undertook a 2-center prospective cohort study in the United Kingdom (UK) (2018) (Clinicaltrials.gov NCT03619733) to specifically assess recalibrated risk scores (shifting the troponin subset scoring from 99th percentile to LOD [UK]) and combined the results of this with secondary analyses of 2 prospective cohort studies in the UK (2011) and the United States (2018, using LOQ rather than LOD). The primary outcome was major adverse cardiovascular events (MACE), defined as adjudicated type 1 myocardial infarction (MI), urgent coronary revascularization, and all-cause death, at 30 days. We evaluated the original scores using hs-cTn below the 99th percentile and recalibrated scores using hs-cTn <LOD/LOQ and compared these composite scores with a single hs-cTnT less than LOD/LOQ combined with a nonischemic ECG. For each discharge strategy, an assessment of clinical effectiveness was also made, defined as the proportion of patients eligible for discharge from the emergency department without the need for further inpatient testing.

RESULTS: We studied 3,752 patients (3,003 in the UK and 749 in the United States). Median age was 58 years, and 48% were female. At 30 days, 330/3,752 (8.8%) experienced MACE. The sensitivities of the original HEART less or equal to 3 and recalibrated HEART less or equal to 3 scores for rule-out were 96.1% (95% confidence interval [CI], 93.4 to 97.9) and 98.6% (95% CI, 96.5 to 99.5) respectively; the original TIMI less or equal to 1 and recalibrated TIMI less or equal to 1 scores' sensitivities were 79.7% (95% CI, 74.9 to 83.9) and 96.1% (95% CI, 93.4 to 97.9) respectively; and nonischemic ECG with hs-cTn T below the 99th percentile and hs-cTn T less than LOD/LOQ was 79.7% (95%CI, 0.749 to 0.839) and 99.1% (95% CI, 0.974 to 0.998), respectively. Recalibrated HEART less or equal to 3 was projected to discharge 14% more patients than hs-cTn T less than LOD/LOQ. The improved sensitivity of rule-out for recalibrated HEART less than or equal to 3 came at the cost of reduced specificity (50.8% versus 53.8% for recalibrated HEART and conventional HEART respectively).

CONCLUSION: This study indicates that recalibrated HEART score of less or equal to 3 is a feasible and safe early discharge strategy using a single presentation hs-cTnT. This finding should be further tested using competitor hs-cTn assays in independent prospective cohorts before implementation.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Khand AU, Backus B, Campbell M, et al. HEART Score Recalibration Using Higher Sensitivity Troponin T. Ann Emerg Med. 2023. PMID: 37306637. doi:10.1016/j.annemergmed.2023.04.024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。